You are probably ready for something more substantial from Right Turn after three weeks of light vacations posts. I have something that fits the bill. Greg Bonfiglio, Founder and Managing Partner of Proteus Venture Partners, was interviewed by PharmaTelevision in May when he attended the World Stem Cells & Regenerative Medicine Congress in London, England.
If you know Mr. Bonfiglio’s background already, his insight into biotech investing in the regenerative medicine (RM) space begins around 3:30. He references immunotherapy companies Juno, bluebird and Kite Pharma as examples of startups that went public and achieved high market capitalizations in very short timeframes. (For more on these companies, read blogger Mark Curtis who has written often about these immunotherapy companies, and others, in his monthly Regenerative Medicine Deal Review posts.)
Wondering about reimbursement? Tune in after 6:30 and hear why Mr. Bonfiglio says the investment community is keen on immunotherapies.
At nine minutes Mr. Bonfiglio offers his perspective on what Big Pharma is doing right now in RM.
If you’re still watching after 11 minutes, the conversation turns to the Centre for Commercialization of Regenerative Medicine (CCRM) and the investment fund that Proteus is developing in partnership with CCRM. Mr. Bonfiglio is chair of CCRM’s Board of Directors.
Our regular feature, Right Turn, appears every Friday and we invite you to submit your own blog to info(at)ccrm.ca. We encourage you to be creative and use the right (!) side of your brain. We dare you to make us laugh! Right Turn features cartoons, photos, videos and other content to amuse, educate and encourage discussion.
As always, we welcome your feedback in the comment section.
Latest posts by Stacey Johnson (see all)
- Right Turn: Stem cell “gun” for wound healing - June 2, 2017
- A few good women: Engineering grads to watch - May 30, 2017
- Right Turn: Eventual relief for those suffering from Crohn’s? - May 26, 2017